Physician profile
Jose E Perez
NPI 1053325803
$1,742.73
in general payments reported to CMS, 2019-2025
21 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $300 · 2021: $12.03 · 2023: $129 · 2024: $302 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.15 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Sunovion Pharmaceuticals INC. | $271.62 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $255.49 | 2019-2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $188.36 | 2019-2020 | |
| United Therapeutics Corporation | $99.19 | 2023-2025 | Tyvaso, Tyvaso, Remodulin |
| Novartis Pharmaceuticals Corporation | $91.25 | 2019-2024 | |
| Insmed, INC. | $62.55 | 2024-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.86 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Ani Pharmaceuticals, INC. | $58.03 | 2023-2024 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $56.13 | 2019-2024 | Yupelri |
| Genzyme Corporation | $38.90 | 2023-2025 | |
| Amgen INC. | $37.14 | 2025 | Tezspire |
| Astellas Pharma US INC | $34.73 | 2025 | Veozah |
| Grifols USA, LLC | $25.64 | 2024 | Prolastin-C Liquid |
| Baxter Healthcare | $25.48 | 2024 | Hillrom - Vest System Model 105 Home Care |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $20.89 | 2019 | |
| Inspire Medical Systems, INC. | $16.99 | 2024 | Inspire |
| Circassia INC. | $15.88 | 2019 | |
| Shire North American Group INC | $11.23 | 2019 | |
| Ceribell, INC. | $11.22 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.